Medarex - 500 Beiträge pro Seite

[volkswagen]

Dain Rauscher Wessels Initiates Coverage On Four Biotechnology Companies

MINNEAPOLIS, May 31, 2000 (BUSINESS WIRE) -- Dain Rauscher Wessels equity
analyst Andrew Milne today initiated coverage on the following biotechnology
companies:


Medarex Inc. (NASDAQ: MEDX), $45.25, with a Strong
Buy-Speculative Risk rating. Milne`s six-month price target is$90.

Dain Rauscher Incorporated managed or co-managed a public offering of the
securities of Medarex Inc. within the past three years. Dain Rauscher
Incorporated also makes a market in IDEC Pharmaceuticals Corporation, Medarex
Inc. and Protein Design Labs Inc. and may act as principal with regard to the
sales or purchases of these securities.

[MSolver]

Habe gerade diese News bekommen:

Medarex and Biosite Combine Leading Antibody Technologies

Trans-Phage Technology(TM) to Enable High Throughput Genomic Medicine


June 1, 2000 06:59 AM Eastern Time
PRINCETON, N.J. and SAN DIEGO, June 1 /PRNewswire/ -- Medarex, Inc. MEDX and Biosite Diagnostics, Inc. BSTE today announced the launch of an alliance aimed at accelerating drug research via Trans-Phage Technology(TM). This high throughput method to create fully human antibodies combines the immunological power of Medarex`s HuMAb-Mouse(TM) with the speed of Biosite`s Omniclonal(TM) phage display technology. Through this alliance Biosite and Medarex will offer pharmaceutical and biotechnology companies access to large volumes of high-affinity, fully human antibodies to validate genomic targets and to identify promising drug candidates.
"Trans-Phage Technology represents the best of both worlds," said Donald L. Drakeman, president and chief executive officer of Medarex. "By working with Biosite, which has used phage technology to develop several products that are now on the market and which has a significant intellectual property portfolio, we will be able to offer our partners a powerful new tool in the effort to bring genomics-based products to reality."

"Over the past eight years, we have used our phage display capabilities to develop mouse antibodies to hundreds of targets. Now with Medarex`s HuMAb-Mice, we can apply our Omniclonal technology to fully human antibodies," said Kim Blickenstaff, president and chief executive officer of Biosite. "Working together, both Medarex and Biosite are positioned to achieve even more significant collaborations with pharmaceutical and biotechnology companies."

Medarex and Biosite believe that the novel Trans-Phage Technology will enable scientists to make large volumes of fully human antibodies to virtually any disease target in a fraction of the time typically associated with traditional technologies. The accelerated process is expected to allow for validation of substantially higher numbers of targets, which could increase the chances of discovering successful targets.

Under the terms of the agreement, Biosite will receive research funding of $3 million per year over eight years from Medarex, along with research fees and, if any products are generated through the collaboration, milestone payments and royalties. Biosite may also receive diagnostic rights to targets identified through the collaboration. Medarex anticipates, as a result of this alliance, receiving payments from third-party collaborators, including milestone payments, royalties and reimbursement payments, that may offset the research funding being paid to Biosite.

Background Information: HuMAb-Mouse and Omniclonal Phage Display Technology

Medarex`s HuMAb-Mouse technology enables the creation of fully human antibodies, avoiding the need for humanization or complicated genetic engineering, which can be time consuming and expensive. Medarex`s HuMAb-Mice are transgenic, meaning that the mouse genes for creating antibodies have been inactivated and replaced by human antibody genes. When HuMAb-Mice are immunized with a target protein, their immune systems create a diverse array of antibodies.

Biosite`s Omniclonal antibody technology employs phage display capabilities and a highly efficient antibody expression and purification process to rapidly generate custom antibody libraries from the array of antibodies created by HuMAb-Mice. Biosite has developed patented methods that enable the selection of large numbers of different antibodies from such libraries. Each selected antibody exhibits high affinity for the target protein, meaning that it binds tightly to the protein.

This combination of Omniclonal and HuMAb technology -- Trans-Phage Technology -- is expected to rapidly produce high-affinity antibodies with substantial diversity, thus enhancing target validation and potentially product development.

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse and TC systems for the creation of high-affinity, fully human antibodies. Using standard, well proven laboratory techniques, scientists can produce these fully human antibodies in a matter of months. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex visit its web site at http://www.medarex.com .

Since its inception in 1988, Biosite Diagnostics Incorporated has been dedicated to meeting important clinical needs in emergency medicine by speeding the flow of critical diagnostic information. Through its integrated discovery and diagnostics businesses, Biosite seeks to develop rapid diagnostic tests that improve clinical and economic outcomes for acute diseases. Biosite`s Triage(R) products are used in 45 percent of U.S. hospitals, as well as several international markets. Information on Biosite can be found at http://www.biosite.com .

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of the company`s product candidates, uncertainties related to business opportunities, the receipt of future payments, the continuation of business partnerships and other risks detailed from time to time in each company`s filings with the Securities and Exchange Commission (SEC).

Biosite(R), Immediate Response Diagnostics(R), Triage(R), Omniclonal(TM) and the Biosite logo are registered trademarks or service marks of Biosite Diagnostics Incorporated.

SOURCE Medarex, Inc.; Biosite Diagnostics, Inc.

[volkswagen]

Medarex, Biosite to collaborate on antibodies

NEW YORK, June 1 (Reuters) - Medarex Inc. and Biosite Diagnostics Inc. said on Thursday they had entered into an alliance for the development of human antibodies using technology from both companies.

Princeton, N.J.-based Medarex <MEDX.O> will combine its HuMAb-Mouse technology with Biosite`s <BSTE.O> Omniclonal phage display technology to offer drug and biotechnology companies access to volumes of human antibodies to validate genomic targets and to identify promising drug candidates.

Under the agreement, Biosite will receive research funding of $3 million per year over eight years from Medarex, along with research fees and, if any products are generated through the collaboration, milestone payments and royalties. Payments from third party collaborators could offset research funding paid to Biosite.

Medarex`s HuMAb-Mouse technology enables the creation of fully human antibodies, meaning that mouse genes for creating antibodies have been replaced by human antibody genes.

Biosite`s Omniclonal antibody technology employs phage display capabilities and a highly efficient antibody expression and purification process to rapidly generate custom antibody libraries from the array of antibodies created by HuMAb-Mice.

((--New York newsroom, 212 859-1700, fax [phone], or [e-mail]))

REUTERS

Rtr 07:47 06-01-00

[MSolver]

Hallo zusammen,
ich gehe davon aus, das dieses die Aktie beflügeln wird. Es würde mich nicht wundern, wenn der Kurs nächsten gegen 65 $ gehen wird.
Ciao

[MSolver]

da haben möglicherweise einige die Zeichen der Zeit nicht erkannt !
seit 13:21 habe ich diese Meldung gepostet und keiner reagiert.